Detail

Basic Information Clinical Results Relationship Graph

Gene symbol	EGFR	Synonyms	ERBB, ERRP, HER1, mENA, ERBB1, PIG61, NISBD2	Type of gene	protein-coding
Chromosome	7	Map location	7p11.2	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	epidermal growth factor receptor

GTO ID	GTC0122
Trial ID	NCT01454596
Disease	Gliosarcoma \| Malignant Glioma \| Brain Cancer \| Glioblastoma
Altered gene	EGFR
Therapeutic/Target gene	Target gene
Therapy	CAR-T cell
Treatment	EGFRvIII CAR-T cells
Generation	3rd
Phase	Phase1\|Phase2
Recruitment status	Completed
Title	CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Year	2011
Country	United States
Company sponsor	National Cancer Institute (NCI)
Other ID(s)	110266\|11-C-0266

Vector information

Vector	retrovirus
Construct	scFv-CD28-4-1BB-CD3ζ
Vector type	γ-retroviral vector (gRV)
Transgene/Inserted gene	epidermal growth factor receptor (EGFR) gene

Cohort1: Steroids_dose1

Administration route	intravenous infusion
Dosage	1E7 cells
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort2: Steroids_dose2

Administration route	intravenous infusion
Dosage	3E7 cells
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort3: Steroids_dose3

Administration route	intravenous infusion
Dosage	1E8 cells
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort4: No Steroids_dose1

Administration route	intravenous infusion
Dosage	1E7 cells
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort5: No Steroids_dose2

Administration route	intravenous infusion
Dosage	3E7 cells
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort6: No Steroids_dose3

Administration route	intravenous infusion
Dosage	1E8 cells
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort7: No Steroids_dose4

Administration route	intravenous infusion
Dosage	3E8 cells
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort8: No Steroids_dose5

Administration route	intravenous infusion
Dosage	1E9 cells
Pts	3
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort9: No Steroids_dose6

Administration route	intravenous infusion
Dosage	3E9 cells
Pts	3
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort10: No Steroids_dose7

Administration route	intravenous infusion
Dosage	1E10 cells
Pts	3
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	no any CAR-T-related severe events
References	PMID: 22780919

Cohort11: No Steroids_dose8

Administration route	intravenous infusion
Dosage	3~6E10 cells
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	1/1(All_cause mortality); 1/1(General disorders)
References	PMID: 22780919

Cohort12: No Steroids_dose9

Administration route	intravenous infusion
Dosage	3E10 cells
Pts	1
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	1/1(Respiratory, thoracic and mediastinal disorders)
References	PMID: 22780919

Overview of Knowledge Graph